Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Luseogliflozin SCHEMBL16155082 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Luseogliflozin SCHEMBL18265378 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Luseogliflozin SCHEMBL27177461 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Luseogliflozin SCHEMBL900678 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Luseogliflozin SCHEMBL29355402 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Luseogliflozin SCHEMBL18629765 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Luseogliflozin SCHEMBL16153589 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Luseogliflozin SCHEMBL17278233 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| SCHEMBL903229 | 0.93 | SLC5A2 (0.87) | SLC5A2SLC5A1 | |
| SCHEMBL17189390 | 0.93 | SLC5A2 (0.87) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000816-A1 | SODIUM-GLUCOSE LINKED TRANSPORTER INHIBITORS FOR THE MANAGEMENT OF CHRONIC KIDNEY DISEASE, HYPERTENSION, AND HEART FAILURE IN COMPANION ANIMALS | INCREVET, INC. | 2023-01-05 | — | — | US | claimed |
| WO-2022117893-A2 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-FORM PHARMA (BE) | 2022-06-09 | — | — | WO | claimed |
| US-20110077212-A1 | THERAPEUTIC USES OF SGLT2 INHIBITORS | THERACOS, INC. (US) | 2011-03-31 | — | — | US | claimed |
| US-20240009167-A1 | AGENT FOR ELIMINATING SENESCENT CELLS | NIIGATA UNIVERSITY (JP) | 2024-01-11 | — | — | US | disclosed |
| US-20230381101-A1 | AQUEOUS PHARMACEUTICAL COMPOSITIONS COMPRISING SGLT-2 INHIBITORS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-11-30 | — | — | US | disclosed |
| US-20230372375-A1 | SGLT-2 INHIBITOR SARCOSINE CO-CRYSTAL, PREPARATION METHOD THEREFOR AND USE THEREOF | OMNISINO HEALTH (TIANJIN) MEDICAL TECHNOLOGY CO. LTD (CN) | 2023-11-23 | — | — | US | disclosed |
| US-11813274-B2 | Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor | HUA MEDICINE (SHANGHAI) LTD. (CN) | 2023-11-14 | — | — | US | disclosed |
| US-11813274-B2 | Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor | HUA MEDICINE (SHANGHAI) LTD. (CN) | 2023-11-14 | — | — | US | disclosed |
| US-11813274-B2 | Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor | HUA MEDICINE (SHANGHAI) LTD. (CN) | 2023-11-14 | — | — | US | disclosed |
| US-11813244-B2 | Agent for eliminating senescent cells | NIIGATA UNIVERSITY (JP) | 2023-11-14 | — | — | US | disclosed |
| US-20230331760-A1 | ARYL GLUCOSIDE DERIVATIVE AND USE THEREOF IN DRUG | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-8017792-B2 | 1-thio-D-glucitol derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-8017792-B2 | 1-thio-D-glucitol derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20110098469-A1 | 1-THIO-D-GLUCITOL DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-04-28 | — | — | US | disclosed |
| US-20110098469-A1 | 1-THIO-D-GLUCITOL DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-04-28 | — | — | US | disclosed |
| US-20110077212-A1 | THERAPEUTIC USES OF SGLT2 INHIBITORS | THERACOS, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-7910619-B2 | e.g. 2,3,4,6-tetra-O-benzyl-5-thio-D-glucono-1,5-lactone3,4-Dihydro-2H-pyran; inhibit the activity of sodium-dependent glucose cotransporter 2 (SGLT2) concerned with glucose reabsorption in the kidney; antidiabetic agent; diabetes-related disease, or diabetic complication | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-22 | — | — | US | disclosed |
| US-7910619-B2 | e.g. 2,3,4,6-tetra-O-benzyl-5-thio-D-glucono-1,5-lactone3,4-Dihydro-2H-pyran; inhibit the activity of sodium-dependent glucose cotransporter 2 (SGLT2) concerned with glucose reabsorption in the kidney; antidiabetic agent; diabetes-related disease, or diabetic complication | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20080132563-A1 | 1-Thio-D-Glucitol Derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
| US-20080132563-A1 | 1-Thio-D-Glucitol Derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372375-A1 | SGLT-2 INHIBITOR SARCOSINE CO-CRYSTAL, PREPARATION METHOD THEREFOR AND USE THEREOF | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885 |
| US-20110098469-A1 | 1-THIO-D-GLUCITOL DERIVATIVES | SLC5A1, SLC5A2, SLC5A11 | SLC5A2 2/4885SLC5A1 1/4885 |
| US-20110077212-A1 | THERAPEUTIC USES OF SGLT2 INHIBITORS | SLC5A2, SLC5A1, PPARG | SLC5A2 1/4885SLC5A1 2/4885 |
| US-20230331760-A1 | ARYL GLUCOSIDE DERIVATIVE AND USE THEREOF IN DRUG | SLC5A1, SLC5A2, SLC10A1 | SLC5A2 2/4885SLC5A1 1/4885 |
| US-11813274-B2 | Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor | SLC5A2, SLC5A1, SLC2A1 | SLC5A2 1/4885SLC5A1 2/4885 |
| US-20230381101-A1 | AQUEOUS PHARMACEUTICAL COMPOSITIONS COMPRISING SGLT-2 INHIBITORS | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885 |
| US-20080132563-A1 | 1-Thio-D-Glucitol Derivatives | SLC5A1, SLC5A2, SLC5A11 | SLC5A2 2/4885SLC5A1 1/4885 |
| US-20230000816-A1 | SODIUM-GLUCOSE LINKED TRANSPORTER INHIBITORS FOR THE MANAGEMENT OF CHRONIC KIDNEY DISEASE, HYPERTENSION, AND HEART FAILURE IN COMPANION ANIMALS | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.